Gastrointestinal Cancer Clinical Trials & Research at Providence Medical Group

Gastrointestinal (GI) cancers encompass a group of malignancies affecting the digestive system, including the esophagus, stomach, liver, pancreas, gallbladder, and intestines. These cancers are among the most prevalent and deadly worldwide, often diagnosed at advanced stages due to the lack of early symptoms. As such, there is a critical need for innovative treatments to improve patient outcomes.

Clinical trials play a vital role in the advancement of GI cancer therapies. These studies are designed to evaluate the safety and efficacy of new treatments, which may include chemotherapy, targeted therapies, immunotherapies, and surgical techniques. By conducting rigorous trials, researchers can identify better ways to treat, manage, and potentially cure GI cancers.

Providence Medical Group is currently enrolling patients for the following Gastrointestinal studies:

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)​

Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA